312 related articles for article (PubMed ID: 28422002)
1. Treatment of psoriasis with ustekinumab improved skin tightening in systemic sclerosis.
Ichihara A; Jinnin M; Ihn H
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):208-210. PubMed ID: 28422002
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
Arakawa A; Ruzicka T; Prinz JC
JAMA Dermatol; 2016 Jul; 152(7):825-8. PubMed ID: 27096382
[TBL] [Abstract][Full Text] [Related]
3. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
Visvanathan S; Baum P; Vinisko R; Schmid R; Flack M; Lalovic B; Kleiner O; Fuentes-Duculan J; Garcet S; Davis JW; Grebe KM; Fine JS; Padula SJ; Krueger JG
J Allergy Clin Immunol; 2019 Jun; 143(6):2158-2169. PubMed ID: 30578873
[TBL] [Abstract][Full Text] [Related]
4. Onset of frontal fibrosing alopecia during inhibition of Th1/17 Pathways with ustekinumab.
King AD; Lam L; Goh C
Dermatol Online J; 2019 Jul; 25(7):. PubMed ID: 31450280
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
[TBL] [Abstract][Full Text] [Related]
6. A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial).
Gelfand JM; Shin DB; Alavi A; Torigian DA; Werner T; Papadopoulos M; Takeshita J; Noe MH; Dey AK; Playford MP; Mehta NN
J Invest Dermatol; 2020 Jan; 140(1):85-93.e2. PubMed ID: 31326395
[TBL] [Abstract][Full Text] [Related]
7. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
Ann N Y Acad Sci; 2011 Mar; 1222():30-9. PubMed ID: 21434940
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of ustekinumab in psoriasis.
Famenini S; Wu JJ
J Drugs Dermatol; 2013 Mar; 12(3):317-20. PubMed ID: 23545915
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
[TBL] [Abstract][Full Text] [Related]
10. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.
Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
Ann N Y Acad Sci; 2012 Aug; 1263():1-12. PubMed ID: 22823582
[TBL] [Abstract][Full Text] [Related]
11. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
Gandhi M; Alwawi E; Gordon KB
Semin Cutan Med Surg; 2010 Mar; 29(1):48-52. PubMed ID: 20430307
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris.
Feldmeyer L; Mylonas A; Demaria O; Mennella A; Yawalkar N; Laffitte E; Hohl D; Gilliet M; Conrad C
JAMA Dermatol; 2017 Apr; 153(4):304-308. PubMed ID: 28122069
[TBL] [Abstract][Full Text] [Related]
13. [Expression and significance of Th17 cells and related cytokines in a murine model of systemic sclerosis].
Lei L; Zhong XN; Zhao C; Mi CD; Li JQ; Zeng JJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Apr; 44(2):259-64. PubMed ID: 22517000
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer.
Quatresooz P; Hermanns-Lê T; Piérard GE; Humbert P; Delvenne P; Piérard-Franchimont C
J Biomed Biotechnol; 2012; 2012():147413. PubMed ID: 22754278
[TBL] [Abstract][Full Text] [Related]
15. Tildrakizumab for treating psoriasis.
Galluzzo M; D'adamio S; Bianchi L; Talamonti M
Expert Opin Biol Ther; 2017 May; 17(5):645-657. PubMed ID: 28271735
[TBL] [Abstract][Full Text] [Related]
16. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis.
Lei L; Zhao C; Qin F; He ZY; Wang X; Zhong XN
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):14-22. PubMed ID: 26750756
[TBL] [Abstract][Full Text] [Related]
17. Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma.
Wang DM; Fernandez AP; Calabrese CM; Calabrese LH
Clin Exp Dermatol; 2019 Jan; 44(1):113-115. PubMed ID: 29797733
[No Abstract] [Full Text] [Related]
18. Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment.
Yeh NL; Hsu CY; Tsai TF; Chiu HY
Clin Drug Investig; 2019 Dec; 39(12):1195-1203. PubMed ID: 31549347
[TBL] [Abstract][Full Text] [Related]
19. New and emerging therapies in psoriasis.
Leonardi CL; Gordon KB
Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S37-41. PubMed ID: 24979544
[TBL] [Abstract][Full Text] [Related]
20. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.
Wada Y; Cardinale I; Khatcherian A; Chu J; Kantor AB; Gottlieb AB; Tatsuta N; Jacobson E; Barsoum J; Krueger JG
PLoS One; 2012; 7(4):e35069. PubMed ID: 22493730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
